Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
PetIQ price target raised to $44 from $33.50 at Guggenheim » 07:07
06/25/20
06/25
07:07
06/25/20
07:07
PETQ

PetIQ

$34.03 /

+1.2 (+3.66%)

, CVET

Covetrus

$18.86 /

+0.27 (+1.45%)

Guggenheim analyst David…

Guggenheim analyst David Westenberg raised the firm's price target on PetIQ (PETQ) to $44 from $33.50 and keeps a Buy rating on the shares. The analyst, who sees the stock having among "the largest upside/downside asymmetry" of the animal health stocks he covers, notes "a large valuation disconnect" between PetIQ and what he views as its closest comp, Covetrus (CVET). Westenberg thinks PetIQ will benefit meaningfully from accelerating adoption of veterinary telemedicine and consumer movement to online channels in a post-COVID-19 world, he added.

ShowHide Related Items >><<
PETQ PetIQ
$34.03 /

+1.2 (+3.66%)

CVET Covetrus
$18.86 /

+0.27 (+1.45%)

PETQ PetIQ
$34.03 /

+1.2 (+3.66%)

05/08/20 SunTrust
PetIQ price target raised to $35 from $30 at SunTrust
CVET Covetrus
$18.86 /

+0.27 (+1.45%)

05/18/20 Spin-Off Research
Covetrus upgraded to Buy from Hold at Spin-Off Research
09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
PETQ PetIQ
$34.03 /

+1.2 (+3.66%)

CVET Covetrus
$18.86 /

+0.27 (+1.45%)

CVET Covetrus
$18.86 /

+0.27 (+1.45%)

Over a month ago
Hot Stocks
Covetrus appoints Arman Samani as chief product officer » 08:47
06/01/20
06/01
08:47
06/01/20
08:47
CVET

Covetrus

$15.28 /

-0.12 (-0.78%)

Covetrus has named Arman…

Covetrus has named Arman Samani to the role of chief product officer. The company said in a release, "Arman will be responsible for developing and driving the vision, roadmap and innovation strategy across Covetrus software products to fuel the company's future growth. Arman will lead global product teams, reporting into Georgia Wraight, executive vice president and president, Global Technology Solutions. Arman was most recently the chief operating officer of AdvancedMD."

ShowHide Related Items >><<
CVET Covetrus
$15.28 /

-0.12 (-0.78%)

CVET Covetrus
$15.28 /

-0.12 (-0.78%)

05/18/20 Spin-Off Research
Covetrus upgraded to Buy from Hold at Spin-Off Research
09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
CVET Covetrus
$15.28 /

-0.12 (-0.78%)

CVET Covetrus
$15.28 /

-0.12 (-0.78%)

Upgrade
Covetrus upgraded to Buy from Hold at Spin-Off Research » 10:11
05/18/20
05/18
10:11
05/18/20
10:11
CVET

Covetrus

$13.67 /

+1.49 (+12.23%)

Spin-Off Research…

Spin-Off Research upgraded Covetrus to Buy from Hold with a $15 price target.

ShowHide Related Items >><<
CVET Covetrus
$13.67 /

+1.49 (+12.23%)

CVET Covetrus
$13.67 /

+1.49 (+12.23%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
CVET Covetrus
$13.67 /

+1.49 (+12.23%)

CVET Covetrus
$13.67 /

+1.49 (+12.23%)

On The Fly
Fly Intel: After-Hours Movers » 19:11
05/14/20
05/14
19:11
05/14/20
19:11
YTEN

Yield10 Bioscience

$4.92 /

-0.02 (-0.40%)

, OPRT

Oportun Financial

$6.00 /

-0.25 (-4.00%)

, DENN

Denny's

$8.77 /

-0.035 (-0.40%)

, ACB

Aurora Cannabis

$6.61 /

+0.79 (+13.57%)

, AEYE

AudioEye

$8.88 /

+0.71 (+8.69%)

, NEWR

New Relic

$58.22 /

+1.62 (+2.86%)

, DDS

Dillard's

$22.94 /

-1.15 (-4.77%)

, AMAT

Applied Materials

$54.51 /

+2.98 (+5.78%)

, GLOB

Globant

$111.38 /

+3.1 (+2.86%)

, OCUL

Ocular Therapeutix

$6.01 /

-0.3 (-4.75%)

, REGN

Regeneron

$569.80 /

-7.58 (-1.31%)

, CODX

Co-Diagnostics

$22.19 /

-1.2 (-5.13%)

, FTCH

Farfetch

$15.94 /

+0.35 (+2.25%)

, CVET

Covetrus

$11.25 /

+0.3 (+2.74%)

, ETON

Eton Pharmaceuticals

$5.20 /

+0.03 (+0.58%)

, AUPH

Aurinia Pharmaceuticals

$17.39 /

-0.19 (-1.08%)

, VVI

Viad

$16.65 /

+0.71 (+4.45%)

, TGTX

TG Therapeutics

$19.90 /

-0.72 (-3.49%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

04/07/20 BTIG
Oportun Financial price target lowered to $19 from $27 at BTIG
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
DENN Denny's
$8.77 /

-0.035 (-0.40%)

04/08/20 Oppenheimer
Denny's price target lowered to $13 from $27 at Oppenheimer
04/01/20 SunTrust
El Pollo Loco upgraded to Buy from Hold at SunTrust
04/01/20 SunTrust
Denny's upgraded to Buy from Hold at SunTrust
03/20/20 Stephens
Denny's price target lowered to $12 from $19 at Stephens
ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

05/13/20 Cantor Fitzgerald
Aurora Cannabis price target raised to C$22 from C$2.75 at Cantor Fitzgerald
04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
02/27/20 Bryan Garnier
Aurora Cannabis downgraded to Sell from Neutral at Bryan Garnier
02/25/20 Needham
Aurora Cannabis initiated with a Hold at Needham
AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

10/24/19 National Securities
AudioEye resumed with a Buy at National Securities
05/31/19 B. Riley FBR
AudioEye selloff brings 'compelling' entry point, syays B. Riley FBR
NEWR New Relic
$58.22 /

+1.62 (+2.86%)

04/27/20 Needham
New Relic price target lowered to $74 from $108 at Needham
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight amid weaker backdrop at Morgan Stanley
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight from Overweight at Morgan Stanley
04/06/20 Rosenblatt
New Relic initiated with a Neutral at Rosenblatt
DDS Dillard's
$22.94 /

-1.15 (-4.77%)

05/07/20 Deutsche Bank
Dillard's price target lowered to $18 from $36 at Deutsche Bank
04/30/20 Wedbush
Dillard's price target lowered to $25 from $63 at Wedbush
01/24/20 Odeon Capital
Dillard's initiated with a Sell at Odeon Capital
11/11/19 Deutsche Bank
L Brands downgraded to Hold from Buy at Deutsche Bank
AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

05/12/20 Susquehanna
Applied Materials fundamentals strong ahead of results, says Susquehanna
05/11/20 Cowen
Applied Materials sales trajectory has positive slope, says Cowen
05/08/20 Wells Fargo
Applied Materials price target raised to $60 from $50 at Wells Fargo
04/14/20 Deutsche Bank
Applied Materials share underperformance unwarranted, says Deutsche Bank
GLOB Globant
$111.38 /

+3.1 (+2.86%)

04/29/20 Goldman Sachs
Globant price target lowered to $130 from $165 at Goldman Sachs
04/16/20 Wedbush
Globant price target lowered to $120 from $150 at Wedbush
03/10/20 KeyBanc
Globant downgraded to Sector Weight from Overweight at KeyBanc
02/21/20 Cantor Fitzgerald
Globant price target raised to $120 from $97 at Cantor Fitzgerald
OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
03/04/20 Piper Sandler
Ocular Therapeutix price target raised to $11 from $7 at Piper Sandler
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

03/09/20 H.C. Wainwright
Co-Diagnostics price target raised to $20 from $4 at H.C. Wainwright
03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
03/30/20 Wells Fargo
Farfetch downgraded to Underweight from Equal Weight at Wells Fargo
02/28/20 KeyBanc
Farfetch price target lowered to $17 from $20 at KeyBanc
11/15/19 Credit Suisse
Farfetch price target lowered to $17 from $22 at Credit Suisse
CVET Covetrus
$11.25 /

+0.3 (+2.74%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

03/30/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $26 from $23 at H.C. Wainwright
01/28/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $23 from $21 at H.C. Wainwright
10/23/19 H.C. Wainwright
Eton Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
09/20/19
Fly Intel: Top five analyst initiations
AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
05/05/20 H.C. Wainwright
TG Therapeutics price target raised to $32 from $24 at H.C. Wainwright
01/17/20 B. Riley FBR
TG Therapeutics price target raised to $25 from $17 at B. Riley FBR
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

  • 15
    May
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

Earnings
Covetrus reports Q1 EBITDA $48M versus $50M in Q1 last year » 16:24
05/14/20
05/14
16:24
05/14/20
16:24
CVET

Covetrus

$11.25 /

+0.3 (+2.74%)

Reports Q1 revenue…

Reports Q1 revenue $1.07B, consensus $1.04B. "I am so proud of our team's accomplishments and their tireless efforts to support our customers across the globe, as we all navigate and adapt to the COVID-19 pandemic. Our strong first quarter results are evidence of the early progress we have achieved by focusing on the core drivers of our business," said Ben Wolin, Covetrus president and chief executive officer. "Veterinary care remains an essential service, and while practices experienced significantly lower client visits during late March and early April, we are encouraged by the moderately improving trends we are beginning to see across many of our customers. As the recovery in our end-market continues, I believe the combination of our strengthened financial profile and organizational health position us well to accelerate growth and create long-term shareholder value." The primary driver of the year-over-year decline was a result of increased selling, general and administrative expense, including transaction-related and strategic consulting costs, and higher interest expense, which offset the increase in gross profit driven by the stronger net sales performance during the first quarter.

ShowHide Related Items >><<
CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

Hot Stocks
Covetrus names Matthew Foulston new CFO » 16:07
05/14/20
05/14
16:07
05/14/20
16:07
CVET

Covetrus

$11.31 /

+0.36 (+3.29%)

Covetrus announced three…

Covetrus announced three additions to its senior leadership team, including global chief financial officer, president of its North American distribution business and global chief information officer. Matthew Foulston will become Covetrus' global chief financial officer effective June 1, 2020, replacing Stuart Gleichenhaus, who has been serving in that role on an interim basis since December 2019. Matthew Malenfant is the incoming president for Covetrus' North American distribution business, effective May 18, 2020. Recently, Malenfant was CEO of Saxco International, a leader in the packaging sector for beverage products. Steve Palmucci joined Covetrus on May 4, 2020 as global chief information officer, replacing Larry Rowland, who had been serving as a consultant and interim CIO since 2018.

ShowHide Related Items >><<
CVET Covetrus
$11.31 /

+0.36 (+3.29%)

CVET Covetrus
$11.31 /

+0.36 (+3.29%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
CVET Covetrus
$11.31 /

+0.36 (+3.29%)

CVET Covetrus
$11.31 /

+0.36 (+3.29%)

Hot Stocks
Covetrus announces $250M convertible preferred equity investment by CD&R » 09:05
04/30/20
04/30
09:05
04/30/20
09:05
CVET

Covetrus

$11.59 /

+1.1 (+10.49%)

Covetrus announced a $250…

Covetrus announced a $250 million investment from Clayton, Dubilier & Rice. This additional capital significantly strengthens the Company's financial profile and enables management to execute against strategic growth objectives. The $250 million in proceeds from the perpetual convertible preferred equity investment will be used to repay a portion of the Company's revolver borrowings, provide additional short-term liquidity, and support general corporate purposes. CD&R will purchase $250 million of perpetual convertible preferred stock that carries a 7.50% dividend, which will be payable in cash or in-kind, at Covetrus' option. The preferred stock will be convertible into shares of Covetrus common stock at a conversion price of $11.10 per share, representing a premium of 40% to Covetrus' thirty-trading day volume-weighted average price and 11% to the five-trading day VWAP. The Company's stock price has increased by 43% since release of preliminary first quarter 2020 results and provision of a business and operational update regarding the COVID-19 pandemic on April 22, 2020. On an as-converted basis, together with CD&R's existing common shares of Covetrus, CD&R will now own approximately 25% of pro forma common shares outstanding. However, the terms of the preferred stock limit CD&R's voting interest to 19.99% of the then-outstanding voting interests in the Company. Under the terms of the transaction agreements, CD&R will have the right to appoint two designees to the Covetrus board of directors.

ShowHide Related Items >><<
CVET Covetrus
$11.59 /

+1.1 (+10.49%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
Hot Stocks
Covetrus takes additional actions to improve cash flow » 08:11
04/22/20
04/22
08:11
04/22/20
08:11
CVET

Covetrus

$8.14 /

-0.45 (-5.24%)

The company said,…

The company said, "Covetrus ended the first quarter of 2020 with $204M in cash and cash equivalents, $1.185B in term loan debt, and $190M drawn on the company's $300M credit facility. In light of market conditions, timing of certain year-end payables and other seasonal working capital dynamics, the Company drew down on its revolver during the first quarter of 2020 to manage its cash position and to maintain additional liquidity in today's uncertain market environment. When financial results are finalized, the Company expects to be in full compliance with its credit agreement as of March 31, 2020. Subsequent to quarter-end, Covetrus announced, on April 1, 2020, the closing of its divestiture of scil animal care to Heska Corporation for $110M or approximately $100M net of deal-related fees and other transaction items. Covetrus used $45M of the proceeds to pre-pay its remaining quarterly term loan principal amortization payments for 2020. Adjusting for these, the Company would have had approximately $259M in cash and cash equivalents and $1.14B in term loan debt. With additional cash outflows expected near-term tied to investing activities and intra-quarter working capital dynamics as well as the unknown impact from COVID-19, the Company is taking additional proactive actions to improve cash flow, including reducing capital expenditures and discretionary spending."

ShowHide Related Items >><<
CVET Covetrus
$8.14 /

-0.45 (-5.24%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
Earnings
Covetrus withdraws 2020 financial guidance » 08:09
04/22/20
04/22
08:09
04/22/20
08:09
CVET

Covetrus

$8.14 /

-0.45 (-5.24%)

The company said,…

The company said, "In light of the uncertain demand outlook caused by COVID-19, Covetrus is withdrawing its previously issued 2020 financial guidance. Among other things, the potential impact of the pandemic on Covetrus' results include: the likelihood of a negative impact on supply chain net sales, particularly in companion animal-related sales as wellness-related veterinary practice visits decline as a result of COVID-19; net sales into the companion animal market represent approximately 75% of the Company's supply chain net sales; the likelihood of a negative impact on certain software-related sales as customers may defer certain purchasing decisions; sales of software solutions represented approximately 2.5% of the Company's net sales in 2019; and the likelihood of a positive impact on prescription management net sales as demand for home delivery services accelerates alongside social distancing measures; prescription management represented approximately 7% of pro forma net sales in 2019. Covetrus plans to provide an additional business update, including the latest COVID-19-related developments, and more details on its first quarter results on its earnings call scheduled for next month."

ShowHide Related Items >><<
CVET Covetrus
$8.14 /

-0.45 (-5.24%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
Hot Stocks
Covetrus says all distribution centers, pharmacies remain open operationally » 08:08
04/22/20
04/22
08:08
04/22/20
08:08
CVET

Covetrus

$8.14 /

-0.45 (-5.24%)

The company said,…

The company said, "Operationally, all of the Company's distribution centers and pharmacies currently remain open as veterinary medicine has been deemed an essential service in most geographies around the globe. Additionally, the Company's supply chain operations continue to work with manufacturers and suppliers across the globe to provide access to critical supplies and quality products, with only personal protective equipment facing significant supply constraints. However, as net sales have weakened over the last four weeks as a result of the impact of COVID-19 on many of the Company's customers, management has taken certain measures to help better align the Company's cost structure near-term, including executive, board and other senior-level employee compensation reductions, employee furloughs in certain European countries, certain shift eliminations, a hiring freeze and discretionary spending deferrals."

ShowHide Related Items >><<
CVET Covetrus
$8.14 /

-0.45 (-5.24%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.